Tyme Technologies — Investor Presentation (June 2017)
24 slides from Tyme Technologies's investor presentation, Jun 15, 2017
Slide 1: TYME for something new
TYME for something new June 2017 Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation and associated oral statements are "forward-looking statements." These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk factors and uncertainties that could cause actual resu
Slide 3: Tyme Overview
Tyme Overview Principle Attack cancer through its natural function rather than attempting to change it Results Complete and partial responses with 13 different cancer types in metastatic setting Duration in some patients maintained for multiple years Safety No serious adverse events related to thera
Slide 4: Common Ties between Cancers
Common Ties between Cancers Discovered in the 1920s Shows that cancer produces energy differently than normal cells Relies on a more primitive metabolic process, called aerobic glycolysis Highly inefficient use of glucose Produces a high level of free radicals (“ROS”) Protective layer that encircles
Slide 5: Breaking the Metabolic Circuit of Cancer
Breaking the Metabolic Circuit of Cancer 3) Protective Mucin Layer Compromised 4) Cell Death From Oxidative Stress Immune Response Free Radicals (ROS) 2) Protein Synthesis Fails 1) Induce Uptake of TYME’s Dysfunctional Tyrosine
Slide 6: SM-88 Composition
SM-88 Composition Dysfunctional Tyrosine Derivative Phenytoin Methoxsalen Rapamycin SM-88 Disrupts cancer’s creation of proteins, including mucin Increases tyrosine uptake Facilitates cell death through oxidative stress Causes the production of more free radicals
Slide 7: Clinical Development Pipeline
Program Formulation Cancer Indication Pre-IND Phase 1 Phase 2 Phase 3 SM-88 Oral Prostate, recurrent non-metastatic Pancreatic, metastatic 3rd Indication, metastatic Injectable Digestively compromised patients Nasal Glioma Transdermal Breast Tyrosine-bound Melanin Oral Various cancers Radiotherapy c
Slide 8: Demonstrated Effectiveness Against Most Common and Deadly Cancers
Demonstrated Effectiveness Against Most Common and Deadly Cancers Source: American Cancer Society. Objective Response Rate (“ORR”) based on imaging analysis using RECIST criteria. Includes both First Human Study and Compassionate Use Patients where data is available (n=87). Primary Disease 2016 US D
Slide 9: SM-88: First Human Study (FHS) Population
SM-88: First Human Study (FHS) Population Enrolled 30 patients during 2012 End-stage metastatic cancer Expected survival 3-6 months Failed or refused all available treatments Patients had no therapy for 60 days prior to receiving SM-88 Summary Patient Overview Progressive disease 26/30 Recurrent dis
Slide 10: SM-88: FHS Progression Free Survival
SM-88: FHS Progression Free Survival All Subjects (n = 30), Monotherapy with SM-88 Median PFS of 14.7 months Study Ended Without Disease Progression (22/30) Death Without Disease Progression (5/30) Disease Progression (3/30) 90% of subjects experienced clinical benefit (CR+PR+SD) 2 complete and 6 pa
Slide 11: SM-88: FHS Progression Free Survival Subgroup Analysis
SM-88: FHS Progression Free Survival Subgroup Analysis Where Penultimate PFS Available (n = 23) Months 2.1x longer PFS on SM-88 than last therapy prior to SM-88 Statistically significant p-value of <0.05 Study Ended Without Disease Progression 15 / 23 Death Without Disease Progression 5 / 23 Disease
Slide 12: SM-88: FHS Selected Efficacy Examples
SM-88: FHS Selected Efficacy Examples Example # Metastatic Cancer Type Prior Therapy (1) Penultimate PFS PFS (2) OS (2) 1 T-Neg. B S,C,R 3 11 11 2 T-Neg. B S,C 5 15 15 3 Pancreatic S n/a 24 24 4 Lung S,C,R 4 26 26 5 Lung C 9 19 19 6 Lung S,C 3 26 27 Achieved long durations of survival in some of the
Slide 13: SM-88: First Human Study Overall Survival
SM-88: First Human Study Overall Survival All Subjects (n = 30), Monotherapy with SM-88 50% SM-88 OS: 25.7 months 3 -6m expected OS 47% ECOG PS ≧2
Slide 14: SM-88: First Human Study Safety Profile
SM-88: First Human Study Safety Profile Median SM-88 exposure: 16.3 weeks, (range: 6-61 weeks) No drug-related SAEs reported in any subjects treated to date, including EAP and current Phase II trial Grade 1/2 Drug-related Adverse Events Reported in SM-88 (n=30) Adverse Events Cycle 1 Subsequent Cycl
Slide 15: Current and Planned Trials
* Current and Planned Trials * TYME
Slide 16: Phase 1b/2 Non-Metastatic Prostate Cancer Interim Clinical Data
Phase 1b/2 Non-Metastatic Prostate Cancer Interim Clinical Data Phase 1b/2 Open-Label Study to Evaluate Safety and Efficacy in Biomarker-Recurrent, Non-Metastatic Prostate Cancer IND filed May 2016 Phase 1b: dose-escalation phase (n=4), completed January 2017 Phase 2: rising prostate specific antige
Slide 17: Presented at ASCO June 5, 2017: Summary of Ongoing Phase 1b/2 Trial
Presented at ASCO June 5, 2017 Summary of Ongoing Phase 1b/2 Trial in Biomarker Recurrent Prostate Cancer Endpoint Evaluable subject response (n=8) Radiographic progression free survival (rPFS) 100.0% CTC count undetectable or significantly improved 87.5% Need for subsequent toxic therapy None PSA d
Slide 18: Phase 2: Metastatic Pancreas Cancer
Phase 2: Metastatic Pancreas Cancer Planned trial summary Indication: Refractory metastatic pancreatic cancer (2L/3L) Therapy: Monotherapy with SM-88, single arm CRO: Quintiles/Novella Sites: ~35 across North America Enrollment: Up to ~120 patients Design: Open-label, with planned interim analysis a
Slide 19: Rationale for Metastatic Pancreas Cancer
Rationale for Metastatic Pancreas Cancer Current prognosis for pancreatic cancer is 80% mortality in first year(1) Standard-of-care results from recent clinical trials: First-line Abraxane + gemcitibine: median OS of 8.5m and CR+PR of 23% First-line FOLFIRINOX: OS of 11m and CR+PR of 31% Second-line
Slide 20: Recent Achievements and Upcoming Objectives
Recent Achievements and Upcoming Objectives Positive interim Phase 1b/2 prostate cancer data published Four additional data publications at ASCO 2017 Preclinical toxicology data released at ESMO 2016 Two core platform patents issued Raised funding for Phase 2 metastatic pancreatic trial Expanded man
Slide 21: APPENDIX
APPENDIX * TYME
Slide 22: Management Team
Steve Hoffman: Co-Founder, Chief Executive and Chief Science Officer >30 years of experience in biochemistry and physics; lead author on over 40 patents Focused on biopharmaceuticals for oncology, metabolic syndrome and central nervous system Previously involved in chemistry, aerospace and laser opt
Slide 23: Non-Executive Directors and Advisory Board
Non-Executive Directors and Advisory Board Non-Executive Board of Directors Dr. Gerald Sokol >30 years as distinguished oncologist and FDA reviewer in oncology division for 27 years David Carberry Chair of audit committee: >40 years in finance, primarily at J&J Timothy C. Tyson >30 years in pharma i
Slide 24: Conclusion
Conclusion Clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer metabolic therapeutics with a broad range of oncology indications Proprietary combination therapy platform designed to breakdown cancer’s cellular defense while simultaneously i
Tyme Technologies — Investor Presentation (June 2017) on 6ix